Barclays
TELO icon

Barclays’s Telomir Pharmaceuticals TELO Stock Holding History

Barclays’s Portfolio TELO Stock Details TELO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$3 – 5519
2025
Q4 		$3 Hold
2
– – ﹤0.01% 5174
2025
Q3 		$3 Sell
2
-3,015
-100% -$4.55K ﹤0.01% 5427
2025
Q2 		$3.77K Sell
3,017
-17,322
-85% -$40K ﹤0.01% 4996
2025
Q1 		$65.7K Sell
20,339
-9,620
-32% -$42K ﹤0.01% 4538
2024
Q4 		$123K Buy
29,959
+22,941
+327% +$108K ﹤0.01% 4535
2024
Q3 		$45.1K Buy
7,018
+5,367
+325% +$26.2K ﹤0.01% 4770
2024
Q2 		$7.94K Buy
+1,651
New +$10.3K ﹤0.01% 4533

Other funds holding TELO

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
WIA
World Investment Advisors Santa Barbara, California $6.2B AUM 19.68% 1-Year Est. Return

Barclays's TELO Position: Q1 2026 in Review

Barclays sold out of Telomir Pharmaceuticals (TELO) in Q1 2026, closing a stake of 2 shares — an estimated $3 sold.

Barclays first reported a position in TELO in Q2 2024 and held it in 7 quarters. The position peaked at $123K in Q4 2024. 27 funds tracked by Wall St. Rank hold TELO as of Q1 2026.

  • Barclays reported no remaining Telomir Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 2 Telomir Pharmaceuticals shares in Q1 2026, an estimated $3.
  • Barclays first reported a position in Telomir Pharmaceuticals in Q2 2024 and held it in 7 quarters.
  • Barclays's Telomir Pharmaceuticals position peaked at $123K in Q4 2024.
  • 27 funds tracked by Wall St. Rank held Telomir Pharmaceuticals as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.